A network meta-analysis of the association between patient traits and response to regular dosing with ICS/long-acting β2-agonist plus short-acting β2 agonist reliever or maintenance and reliever therapy for asthma

Current treatment for moderate –severe asthma with inhaled corticosteroid (ICS)-based therapy can follow two strategies: a single inhaler maintenance and reliever therapy (MART) regimen, or regular dosing with ICS/long-acting β2-agonist used as maintenance therapy plus a separate short acting β2-agonist reliever inhaler. It w ould be clinically useful to understand the potential of patient traits to influence regular dosing or MART treatment outcomes.

Source: Respiratory Medicine - July 29, 2023 Category: Respiratory Medicine Authors: Arzu Yorganc ıoğlu, Alvaro A. Cruz, Gabriel Garcia, Kim L. Lavoie, Nicolas Roche, P.G. Abhijith, Manish Verma, Anurita Majumdar, Swarnendu Chatterjee Tags: Original Research Source Type: research